Carregant...
The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review
BACKGROUND: Monoclonal antibodies (mAbs) approved for use as add-on therapy in patients with severe asthma target the underlying pathogenesis of asthma. MAIN BODY: Omalizumab binds immunoglobulin E (IgE), thereby inhibiting its interaction with the high-affinity IgE receptor and reducing the quantit...
Guardat en:
| Publicat a: | Respir Res |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6097430/ https://ncbi.nlm.nih.gov/pubmed/30115042 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-018-0859-z |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|